|
Shire
opens Dubai office
(Dubai) -
Shire plc (LSE: SHP, NASDAQ:
SHPG), a global biotech
company targeting rare
diseases,
formally opens its new
office
in Dubai, United Arab
Emirates (UAE), in the
presence of
His Excellency Dr. Amin
Hussain
Alameeri,
Assistant Undersecretary of
Public Health Policy and
Licensing at the UAE
Ministry of Health and
Prevention,
and
Her Excellency
Dr.
Maryam
Matar,
Founder and Chairperson of
UAE Genetic Disease
Association participated in the new office launch as an honorary guest.
The
new
site
will serve as a
regional hub for Shire’s
Eurasia, Middle East and
Africa operations (EAMEA),
overseeing a network of 10
local offices and activity
spanning 30 countries.
Nearly one
in
20
people living in the region
suffer from
rare diseases,
many of them
children.
The Dubai hub will support Shire’s commitment to accelerating
access to life-changing rare
disease treatments for
patients by helping to
strengthen relationships
with stakeholders in
academic research, clinical
practice, regulatory affairs
and medical innovation.
It is estimated that around
350 million
people
worldwide
are affected by rare diseases1
- an estimated
2.8
million of them are across
the
Middle East.2
Rare diseases are associated
with lifelong suffering and
a shorter lifespan.3
Nearly 50% of rare
conditions begin in
childhood, 3 and
30% of children with a rare
disease will not live to see
their 5th birthday.1
Following Shire’s
combination with Baxalta in
2016, the company is now
recognized as one of the
leading global biotechnology
company that focuses on
serving people with rare
diseases and highly
specialized conditions. With
24,000 employees worldwide,
Shire brings more than 40
therapies to patients in
over 100 countries. Every
year, Shire invests over 1.4
billion US dollars in the
complex and risky process of
developing breakthrough
medicines for conditions
with high unmet need. Today,
Shire’s pipeline is the
deepest and most innovative
in the company’s history,
with more than 40 clinical
trials underway.
Shire is enhancing
capabilities and investing
in sites and workplaces
around the world. The Dubai
office is one of the first
places in the EAMEA region
where employees from both
companies Shire and Baxalta
will come together as one
team.
His Excellency Dr. Amin
Hussain
Al
Amiri,
the UAE’s
Assistant Undersecretary of
Public Health Policy and
Licensing,
commented:
"We are delighted that Shire
has chosen the United Arab
Emirates to be the regional
hub for its EAMEA operations
and share their ambition and
commitment to create
innovative healthcare
solutions that benefit the
underserved rare-disease
patient community. This
aligns
with the UAE's Vision 2021
National Agenda of
implementing a world-class
healthcare system as we
continue to drive innovation
and improve access to new
medicines. Shire’s position
as the global biotech leader
in rare diseases will help
us to develop solutions
together for the UAE and the
wider EAMEA region."
Dr. Alameeri continued:
"The Ministry of Health
and Prevention’s strategy is
to develop a robust
regulatory and investment
framework that safeguards
the intellectual property
and innovation across the
drug development sector,
paving the way for the UAE
to become an attractive
destination for global
pharmaceutical companies who
are encouraged to launch
their regional operations as
well as their logistic
distribution hubs. This also
provides companies the
opportunity to register
their treatment and
therapies, which will help
support patients, and the
overall treatment cycle,
medical tourism objectives
in the UAE. The drug
registration process in the
UAE allows for the
availability of innovative
treatment to be ready
immediately after being
approved from the United
States’ FDA or the European
Medicine Agency as the
second or third country in
the world."
The total number of
scientific offices available
in the UAE is 47 offices,
which represents leading
multinational drug
production companies. It is
expected that the number of
scientific offices increases
to 75 by the year 2021,
where investments have
exceeded AED 3 billion
annually.
Furthermore, there are 18
drug production plants in
the UAE with the expectation
to have them increase to 34
by the year 2021. The
Ministry supports local
production facilities by
driving strategic
partnerships with
international manufacturers
to produce innovative
medicine for the UAE.
Her Excellency Dr. Maryam
Matar
said: "Shire's commitment to
rare diseases, their
pioneering work in the
research and policy and
procedures, in the field of
rare diseases is one of the
biggest reasons for us to
support their presence in
the UAE and hence their
entry in the Arab world. UAE
Genetic Diseases Association
is founded on the pillars of
research and sharing
knowledge and we see these
as two opportunities to
collaborate with Shire in
the future."
Dr. Ramsey Morad, Vice
President, Shire Eurasia,
Middle East and Africa,
commented:
Our ambition at Shire is
to change the future for
people with rare diseases
and we’re working hard to
accelerate patient access to
our next-generation
therapies. Shire EAMEA now
employs nearly 500 people
around the region and we’re
committed to growth. We
already provide 25 different
rare-disease treatments to
thousands of patients in the
EAMEA region and have a
number of important new
launches planned over the
next year."
Ramsey Morad, continued:
"Our work doesn’t stop here. Of the 7,000 known rare diseases, only
5% have a treatment. Time
matters in the fight against
rare diseases, and every day
offers an opportunity to
help patients. I am
therefore delighted to be
opening these new Dubai
offices, designed to support
our team by fostering
collaboration, innovation
and wellbeing and we are
honored that His Excellency,
Dr. Amin Hussain Alameeri,
is here to mark this special
event. All of us at Shire
are excited to be developing
our capabilities and
investing in the region as
we strive to improve the
lives of people with rare
diseases and other high-need
conditions. They often face
incredible challenges every
day of their lives."
Related Link:
Shire Plc
REFERENCES:
1.
Global
Genes. Factsheet on Rare
Diseases. 2016:
https://globalgenes.org/rare-diseases-facts-statistics/.
Accessed 26 September 2017
2. Almalki Z.
et al. Intractable Rare Dis
Res. 2012 Nov; 1(4):
139–143:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204565/.
Accessed 26 September 2017
3.
EURORDIS.
Position paper - Rare
diseases: understanding this
public health priority.
2005:
http://www.eurordis.org/IMG/pdf/princeps_document-EN.pdf
Accessed 26
September 2017
PRINT
THIS ARTICLE
|